Transgene Biotek (BSE: TRABI) is loss-making over the last 12 months, losing ₹1.61 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹2.49, 41% below its 52-week high. Sales grew 56% a year over 3 years. Debt is 2.05× equity. It is a small-cap company with a market cap of ₹19 Cr, ranked 17th of 20 Biotechnology companies by market cap; the shares fell 30% over the past year.
- ₹2.50
- ₹2.75
- ₹2.27
- ₹2.52
- 17.1K
Health check
- ReturnsBehind
−29.6% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +56.5% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -0.5% vs peer median 16.7%.
- Balance sheetStretched
Debt 2.05× equity, operating profit doesn’t cover interest, Piotroski 2 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹19 Cr
- Small cap
- P/E
- n/a
- Industry 49.1
- Price to book
- 2.25
- Peers 4.68
- Dividend yield
- 0.00%
- ROE
- −18.0%
- Peers 14.3%
- ROCE
- −0.5%
- Peers 16.7%
- Debt to equity
- 2.05
- Debt ₹17 Cr
- EPS (TTM)
- −₹0.21
- OPM (TTM)
- −208.9%
- Net margin 0.0%
- Sales growth
- +21.2%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 85.10
- EV/EBITDA −83.9
Strengths and risks
Strengths
- Quarterly sales up 21.2% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −18.0%.
- Debt is 2.05× equity.
- 41% below its 52-week high.
- Interest coverage of only −0.5×.
About Transgene Biotek
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat…
- Headquarters
- Sangareddy
- Sector
- Healthcare
- ISIN
- INE773D01018
- Website
- transgenebiotek.com
Price range
- Avg volume (3M)
- 23.7K
- 1-year return
- minus 29.6%
- From 52-week high
- minus 40.6%
Peers · Biotechnology
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | 365.10 | plus 0.86% | 59,794 | 122.5 | 1.73 | 2.8% | 1.0% | 19.4% | 15.3% | −5.9% | 0.14% | minus 4.9% |
| ANTHEMAnthem Biosciences | 915.55 | plus 0.22% | 51,594 | 84.6 | 15.74 | 26.8% | 20.4% | 41.4% | 26.2% | 15.4% | 0.22% | plus 30.1% |
| ONESOURCEOnesource Specialty Pharma | 1,599.80 | plus 1.13% | 18,346 | – | 3.10 | 0.3% | 0.0% | 23.5% | 232.3% | – | 0.00% | minus 13.7% |
| CONCORDBIOConcord Biotech | 632.60 | minus 5.96% | 13,236 | 47.4 | 6.48 | 16.7% | 14.3% | 34.5% | 8.0% | 2.8% | 0.60% | minus 7.5% |
| BLUEJETBlue Jet Healthcare | 553.80 | minus 3.91% | 9,607 | 34.5 | 4.52 | 24.0% | 19.9% | 31.4% | 9.4% | 15.7% | 0.22% | minus 5.0% |
| SUPRIYASupriya Lifescience | 695.80 | minus 19.99% | 5,600 | 28.2 | 4.68 | 22.3% | 19.1% | 21.4% | 21.2% | 32.5% | 0.14% | plus 9.2% |
| ZOTAZota Health Care | 1,231.10 | plus 1.01% | 4,264 | – | 6.82 | −7.3% | −24.1% | 0.1% | 56.7% | – | 0.08% | minus 21.9% |
| TRABITransgene Biotek | 2.49 | minus 1.19% | 19 | – | 2.25 | −0.5% | −18.0% | −208.9% | 56.5% | – | 0.00% | minus 29.6% |
| Median of 7 peers | – | 0.22% | 13,236 | 47.4 | 4.68 | 16.7% | 14.3% | 23.5% | 21.2% | 15.4% | 0.14% | −5.0% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 0 | 0.1 | 0.1 | 0.1 | 0.1 | |
| 0.2 | 0.1 | 0.1 | 0.3 | 0.1 | |
| −0.1 | −0.1 | −0.1 | −0.3 | −0.1 | |
| −279.6% | −140.7% | −92.5% | −514.1% | −97.3% | |
| 0 | 0 | −0 | 0.1 | 0 | |
| 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | |
| 0 | 0 | 0 | 0 | 0 | |
| −0.4 | −0.4 | −0.4 | −0.5 | −0.4 | |
| −0.4 | −0.4 | −0.4 | −0.5 | −0.4 | |
| -0.06 | -0.05 | -0.05 | -0.06 | -0.05 |
Profit & loss
- Sales CAGR 3Y
- +56.5%
- ROE
- −18.0%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0.1 | 0.2 | 0.3 | 0.2 | |
| – | +326.3% | +11.0% | minus 19.0% | |
| 0.5 | 0.7 | 1.4 | 0.8 | |
| −0.4 | −0.4 | −1.1 | −0.5 | |
| −785.8% | −180.2% | −430.9% | −257.3% | |
| −0 | −0 | 0.8 | 0.1 | |
| 0.6 | 0.1 | 0.2 | 1.1 | |
| 5 | 0.1 | 0.1 | 0.2 | |
| −6 | −0.7 | −0.7 | −1.7 | |
| −6 | −0.7 | −0.7 | −1.7 | |
| -0.79 | -0.09 | -0.09 | -0.22 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 75.8 | 75.8 | 75.8 | 75.8 | |
| −64.4 | −65.1 | −65.7 | −67.4 | |
| 13.1 | 14 | 14.5 | 17.1 | |
| 118 | 118 | 120 | 118 | |
| 142 | 142 | 144 | 144 | |
| 1.8 | 1.7 | 3.3 | 3.1 | |
| 0 | 0 | 0.3 | 0.1 | |
| 141 | 141 | 141 | 141 | |
| 142 | 142 | 144 | 144 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0 | 0 | 1.2 | −0 | |
| −0 | – | −1.7 | 0.2 | |
| – | – | 0.8 | −0.4 | |
| −0 | 0 | 0.3 | −0.2 | |
| −0 | – | −1.7 | – | |
| −0 | 0 | −0.5 | −0 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.